Synlogic (SYBX) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Offering details and pricing
Registration statement filed to offer securities from time to time after the effective date, as determined by the registrant.
Securities may be offered on a delayed or continuous basis under Rule 415.
The registration statement is an amendment to Form S-3, filed to include new exhibits.
Management team and governance
Principal Executive Officer and Principal Financial Officer is Mary Beth Dooley.
Board of Directors includes Peter Barrett (Chairman), James Flynn, Edward Mathers, and Richard P. Shea.
Underwriters and syndicate
Legal counsel includes Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Synlogic
- Entered merger with Caldera Therapeutics after restructuring and reporting a Q2 net loss of $0.54M.SYBX
Q2 2026 - Q1 2026 net income increased to $0.7M, driven by warrant gains amid ongoing strategic review.SYBX
Q1 2026 - Restructured as a shell after discontinuing clinical programs, with sharply reduced expenses and a $1M net loss.SYBX
Q4 2025 - Biopharma seeks $150M shelf offering after pivoting to strategic alternatives post-trial halt.SYBX
Registration Filing - Annual Meeting to vote on director, executive pay, and auditor, with strong governance focus.SYBX
Proxy Filing - Net loss narrowed to $2.3M in Q3 2025 amid restructuring and strategic review.SYBX
Q3 2025 - Annual Meeting to vote on directors, executive pay, new equity plan, and auditor ratification.SYBX
Proxy Filing - Losses narrowed sharply after restructuring and trial discontinuation; strategic review ongoing.SYBX
Q2 2025 - Lead program ended, costs cut, and strategic options under review with $19.4M cash on hand.SYBX
Q3 2024